8-K
filed June 8, 2023, 7:59 PM ET
ticker ABOS
CIK 0001576885
other material
confidence high
sentiment neutral
materiality 0.50
Acumen shareholders approve officer exculpation amendment; re-elect directors
Acumen Pharmaceuticals, Inc.
- Shareholders approved certificate amendment to allow officer exculpation per Delaware law (27,061,448 votes for, 99.9% of votes cast).
- Re-elected Dr. Derrell Porter (27,096,949 for) and Dr. Laura Stoppel (24,440,807 for) as Class II directors until 2026.
- Ratified Ernst & Young as independent auditor for FY2023 with 36,099,071 votes for, 185 against, 214 abstained.
- Quorum of 36,099,470 shares (87.99% of 41,025,062 outstanding) present at annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Acumen Pharmaceuticals, Inc.: Amended certificate of incorporation to reflect Delaware law provisions allowing for exculpation of officers (effective 2023-06-06).
- Change
- charter amendment
- Effective
- 2023-06-06
Exact text from the filing
On June 6, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) held its 2023 annual meeting of stockholders (the “ Annual Meeting ”). As described in Item 5.07 below, the Company’s stockholders approved the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ” and, as amended, the “ Amended Certificate of Incorporation ”) to reflect Delaware law provisions allowing for the exculpation of officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Acumen Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-06-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal No. 1: The stockholders elected two nominees to serve as Class II directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Derrell Porter, M.D. 27,096,949 5,040 Laura Stoppel, Ph.D. 24,440,807 2,661,182
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Acumen Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 36,099,071 185 214
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Acumen Pharmaceuticals, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to reflect Delaware law provisions allowing for exculpation of officers at the 2023-06-06 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal No. 3: The stockholders approved an amendment to the Company’s Certificate of Incorporation to reflect Delaware law provisions allowing for the exculpation of officers. The votes were cast as follows: Votes For Votes Against Abstained Amendment to Certificate of Incorporation 27,061,448 39,649 892
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.